Fewer Worsening Heart Failure Events With HeartLogic on top of Standard Care: a Propensity-Matched Cohort Analysis

Michelle Feijen1, Monika Beles2, Yan Zhi Tan3

  • 1Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.

Insights

The HeartLogic algorithm, used with implantable cardiac defibrillators, reduces worsening heart failure (HF) events and hospitalizations for fluid retention when added to standard care.

Area of Science:

  • Cardiology
  • Medical Devices
  • Digital Health

Background:

  • Heart failure (HF) management often involves monitoring for fluid retention.
  • The HeartLogic algorithm, integrated with implantable cardiac defibrillators (ICDs), is designed to predict impending fluid retention.
  • Prior studies confirm the safety of HeartLogic integration into clinical practice.

Purpose of the Study:

  • To evaluate the clinical benefit of the HeartLogic algorithm beyond standard care and device telemonitoring in HF patients.
  • To determine if HeartLogic reduces worsening HF events and associated hospitalizations.

Main Methods:

  • A multicenter, retrospective, propensity-matched cohort analysis compared HeartLogic to conventional telemonitoring in HF patients with ICDs.
  • The primary endpoint was the number of worsening HF events.
  • Secondary endpoints included HF hospitalizations and ambulatory visits for diuretic escalation.

Main Results:

  • The HeartLogic group experienced fewer worsening HF events (1 vs 2; P=0.004) compared to the control group.
  • HF hospitalization days were significantly shorter in the HeartLogic group (5 vs 8 days; P=0.023).
  • Ambulatory visits for diuretic escalation were also reduced in the HeartLogic group (1 vs 2; P=0.0001).

Conclusions:

  • Integrating the HeartLogic algorithm into HF care pathways improves patient outcomes.
  • HeartLogic, when added to standard care and telemonitoring, is associated with a reduction in worsening HF events.
  • The algorithm contributes to shorter hospitalizations related to fluid retention in heart failure patients.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
28
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
472
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
645
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
18
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
17